SG/PUT/ASTRAZENECA/10000/0.1/20.12.24 | Market Closed - Deutsche Boerse AG 20:36:54 25/06/2024 BST | ||
| 0.14 EUR | -6.67% |
|
| Current month | -33.33% | ||
| 1 month | -30.00% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ASTRAZENECA PLC
Latest news about ASTRAZENECA PLC
More news
| Date | Price | Change |
|---|---|---|
| 25/06/24 | 0.14 | -6.67% |
| 24/06/24 | 0.15 | -6.25% |
| 21/06/24 | 0.16 | 0.00% |
| 20/06/24 | 0.16 | -11.11% |
| 19/06/24 | 0.18 | 0.00% |
Delayed Quote Deutsche Boerse AG
Last update June 25, 2024 at 08:36 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | PUT |
| Underlying | ASTRAZENECA PLC |
| Issuer | 
Société Générale
|
| WKN | SU13YE |
| ISIN | DE000SU13YE0 |
| Date issued | 13/11/2023 |
| Strike | 10,000 p |
| Maturity | 20/12/2024 (178 Days) |
| Parity | 10 : 1 |
| Emission price | 0.92 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1.2 € |
|---|---|
| Lowest since issue | 0.14 € |
| Spread | 0.03 € |
| Spread % | 17.65% |
Company Profile
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
-
Consensus: AstraZeneca PLC
Sell
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
159
USD
Average target price
174.4
USD
Spread / Average Target
+9.68%
- Stock Market
- Warrants
- Warrant
